Patents by Inventor Mark A. Olson
Mark A. Olson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9133253Abstract: Disclosed herein ricin toxin A chain polypeptides having an engineered disulfide bond ((SS)RTA) and compositions thereof. The disclosed (SS)RTA polypeptides retain the immunological epitope of wild type RTA, lack detectable N-glycosidase activity or exhibit reduced N-glycosidase activity as compared to controls, and exhibit increased solubility, thermal stability and a lower tendency to self-aggregate as compared to RTA 198 and/or RTA 1-33/44-198. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, inhibiting, reducing and/and preventing ricin intoxication are disclosed.Type: GrantFiled: April 21, 2011Date of Patent: September 15, 2015Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Patricia M. Legler, Jaimee R. Compton, Charles B. Millard, Mark A. Olson
-
Patent number: 8710185Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: GrantFiled: November 28, 2011Date of Patent: April 29, 2014Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert G. Ulrích, Mark A. Olson, Sina Bavari
-
Publication number: 20130295101Abstract: Disclosed herein ricin toxin A chain polypeptides having an engineered disulfide bond ((SS)RTA) and compositions thereof. The disclosed (SS)RTA polypeptides retain the immunological epitope of wild type RTA, lack detectable N-glycosidase activity or exhibit reduced N-glycosidase activity as compared to controls, and exhibit increased solubility, thermal stability and a lower tendency to self-aggregate as compared to RTA 198 and/or RTA 1-33/44-198. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, inhibiting, reducing and/and preventing ricin intoxication are disclosed.Type: ApplicationFiled: April 21, 2011Publication date: November 7, 2013Inventors: Patricia M. Legler, Jaimee R. Compton, Charles B. Millard, Mark A. Olson
-
Publication number: 20120148601Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: November 28, 2011Publication date: June 14, 2012Inventors: ROBERT G. ULRICH, Mark A. Olson, Sina Bavari
-
Publication number: 20120100507Abstract: A method of forming a dental matrix includes providing a strip of PTFE tape of a length sufficient to cover a portion of a patient's mouth during a dental procedure, drying the portion of the patient's mouth to which the strip of PTFE tape is to be applied, applying the strip of PTFE tape by stretching the PTFE tape over the portion of the patient's mouth to be protected from exposure to substances used in the at least one dental procedure thus causing the strip of PTFE tape to adhere to the patient's mouth over the portion to be protected, performing the dental procedure, and removing the strip of PTFE tape from the patient's mouth.Type: ApplicationFiled: October 25, 2010Publication date: April 26, 2012Inventor: Mark A. Olson
-
Patent number: 8067202Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: GrantFiled: May 7, 2008Date of Patent: November 29, 2011Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert G. Ulrich, Mark A. Olson, Sina Bavari
-
Publication number: 20090068226Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: May 7, 2008Publication date: March 12, 2009Inventors: Robert G. Ulrich, Mark A. Olson, Sina Bavari
-
Patent number: 7407935Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.Type: GrantFiled: August 23, 2004Date of Patent: August 5, 2008Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher
-
Patent number: 7378257Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: GrantFiled: January 29, 2004Date of Patent: May 27, 2008Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert G. Ulrich, Mark A. Olson, Sina Bavari
-
Patent number: 7219916Abstract: A snowboard has elongate runners integrally formed with the bottom surface of the snowboard to increase the downhill speed characteristics of the snowboard. The runners define a longitudinally extending channel thereinbetween. The cross-sectional thickness of the snowboard is thicker at the runners and becomes thinner along the channel to increase the stiffness of the snowboard without significantly increasing the weight of the snowboard.Type: GrantFiled: October 7, 2004Date of Patent: May 22, 2007Inventor: Mark A. Olson
-
Patent number: 6869787Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.Type: GrantFiled: February 27, 2002Date of Patent: March 22, 2005Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher, Ross D. LeClaire
-
Patent number: 6713284Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: GrantFiled: June 25, 1997Date of Patent: March 30, 2004Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert G. Ulrich, Mark A. Olson, Sina Bavari
-
Publication number: 20030181665Abstract: Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.Type: ApplicationFiled: February 27, 2002Publication date: September 25, 2003Inventors: Mark A. Olson, Charles B. Millard, Michael P. Byrne, Robert W. Wannemacher, Ross D. LeClaire
-
Publication number: 20030009015Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: ApplicationFiled: June 25, 1997Publication date: January 9, 2003Inventors: ROBERT G. ULRICH, MARK A. OLSON, SINA BAVARI
-
Patent number: 6399332Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.Type: GrantFiled: September 1, 1998Date of Patent: June 4, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert G. Ulrich, Mark A. Olson, Sina Bavari
-
Publication number: 20020013757Abstract: An automated exchange system is provided which includes a smart electronic double auction for allocating audience items among perspective buyers and sellers and for calculating a set of prices for the audience items, i.e. any form of advertising time and/or space in any media environment, based on buyer bids and seller offers. The system and method includes processing bids and offers, identifying a set of trades in audience items between buyers and sellers which optimize gains obtained by buyers and sellers from the set of trades in the audience items and calculating a price for each item. The system and method effectively processes participants' complex preferences for multiple, heterogeneous, multi-dimensional audience items while providing substantial efficiency advantages, such as reduced transaction costs.Type: ApplicationFiled: December 8, 2000Publication date: January 31, 2002Inventors: Mark M. Bykowsky, Mark A. Olson, Stephen Rassenti, Anne M. Sholtz